CytomX Therapeutics, Inc. Balance Sheet
CTMX / Health Care|13 years of annual SEC 10-K data (FY2013-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 13 fiscal years. All figures from audited SEC 10-K filings.
CytomX Therapeutics, Inc. had $152M in total assets and $99M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.7M | $38.1M | $17.2M | $193.7M | $205.5M | $191.9M | $188.4M | $247.6M | $177.5M | $104.6M | $8.7M | $64.4M | $8.7M |
| Accounts Receivable | $2.0M | $3.1M | $3.4M | $36.0M | $790.0K | $798.0K | $13.0K | $97.0K | $10.1M | $2.2M | $744.0K | $1.9M | - |
| Current Assets | $143.9M | $107.3M | $182.9M | $237.1M | $310.3M | $324.0M | $303.3M | $445.5M | $388.6M | $188.1M | $189.8M | $66.9M | - |
| PP&E (Net) | $1.3M | $2.5M | $4.0M | $5.1M | $6.0M | $7.0M | $7.4M | $6.9M | $4.2M | $4.4M | $3.5M | $3.0M | - |
| Goodwill | $949.0K | $949.0K | $949.0K | $949.0K | $949.0K | $949.0K | $949.0K | $949.0K | $949.0K | $949.0K | $949.0K | $949.0K | - |
| Total Assets | $151.6M | $120.5M | $201.8M | $260.9M | $339.4M | $358.7M | $341.3M | $457.1M | $397.6M | $199.1M | $197.2M | $73.1M | - |
| Current Liabilities | $46.6M | $85.8M | $155.9M | $152.6M | $106.3M | $100.9M | $85.6M | $97.9M | $61.1M | $35.8M | $15.7M | $11.2M | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | $1.6M | - |
| Shareholders' Equity | $99.0M | -$456.0K | -$47.4M | -$85.8M | -$459.0K | -$7.8M | $51.1M | $130.9M | $69.9M | $78.5M | -$44.3M | -$78.5M | -$44.3M |